{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:29:23Z","timestamp":1773102563110,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00520-023-08193-5","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:02:03Z","timestamp":1701216123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renin\u2013angiotensin\u2013aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-6328","authenticated-orcid":false,"given":"Yasutaka","family":"Ihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7245-4990","authenticated-orcid":false,"given":"Kenji","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-3467","authenticated-orcid":false,"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5416-3401","authenticated-orcid":false,"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6605-7805","authenticated-orcid":false,"given":"Miho","family":"Otani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3880-762X","authenticated-orcid":false,"given":"Ryota","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5498-0564","authenticated-orcid":false,"given":"Shingo","family":"Takatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-110X","authenticated-orcid":false,"given":"Ayumi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"issue":"3","key":"8193_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/14651858.CD013257.pub2","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.1002\/14651858.CD013257.pub2","journal-title":"CA Cancer J Clin"},{"key":"8193_CR2","unstructured":"World Health Organization (2020) WHO report on cancer: setting priorities, investing wisely and providing care for all Geneva; World Health Organization: Geneva, Switzerland; License: CC BY-NC-SA 3.0 IGO"},{"issue":"5","key":"8193_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/WCO.0000000000000234","volume":"28","author":"G Cavaletti","year":"2015","unstructured":"Cavaletti G, Marmiroli P (2015) Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol 28(5):500\u2013507. https:\/\/doi.org\/10.1097\/WCO.0000000000000234","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 2","key":"8193_CR4","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/jns.12335","volume":"24","author":"NP Staff","year":"2019","unstructured":"Staff NP, Cavaletti G, Islam B et al (2019) Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S26\u2013S39. https:\/\/doi.org\/10.1111\/jns.12335","journal-title":"J Peripher Nerv Syst"},{"issue":"Suppl 2","key":"8193_CR5","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1111\/jns.12336","volume":"24","author":"S Tamburin","year":"2019","unstructured":"Tamburin S, Par SB, Alberti P et al (2019) Taxane and epothilone-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S40\u2013S51. https:\/\/doi.org\/10.1111\/jns.12336","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"8193_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/0284186X.2014.995775","volume":"54","author":"M Ewertz","year":"2015","unstructured":"Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54(5):587\u2013591. https:\/\/doi.org\/10.3109\/0284186X.2014.995775","journal-title":"Acta Oncol"},{"issue":"3","key":"8193_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","volume":"125","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Weimer LH, Wang A et al (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767\u2013774. https:\/\/doi.org\/10.1007\/s10549-010-1278-0","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"8193_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3747\/co.21.1984","volume":"21","author":"JS Hong","year":"2014","unstructured":"Hong JS, Tian J, Wu LH (2014) The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol 21(4):174\u2013180. https:\/\/doi.org\/10.3747\/co.21.1984","journal-title":"Curr Oncol"},{"issue":"28","key":"8193_CR9","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325\u20133348. https:\/\/doi.org\/10.1200\/JCO.20.01399","journal-title":"J Clin Oncol"},{"issue":"13","key":"8193_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359\u20131367. https:\/\/doi.org\/10.1001\/jama.2013.2813","journal-title":"JAMA"},{"issue":"18","key":"8193_CR11","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","volume":"32","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941\u20131967. https:\/\/doi.org\/10.1200\/JCO.2013.54.0914","journal-title":"J Clin Oncol"},{"issue":"6","key":"8193_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/jnci\/djz011","volume":"111","author":"SG Dorsey","year":"2019","unstructured":"Dorsey SG, Kleckner IR, Barton D et al (2019) The National Cancer Institute Clinical Trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst 111(6):531\u2013537. https:\/\/doi.org\/10.1093\/jnci\/djz011","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"8193_CR13","doi-asserted-by":"publisher","first-page":"7408","DOI":"10.1007\/s12035-019-1616-0","volume":"56","author":"E Kim","year":"2019","unstructured":"Kim E, Hwang S-H, Kim H-K, Abdi S, Kim HK (2019) Losartan, an angiotensin II type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia. Mol Neurobiol 56(11):7408\u20137419. https:\/\/doi.org\/10.1007\/s12035-019-1616-0","journal-title":"Mol Neurobiol"},{"issue":"2","key":"8193_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1248\/bpb.b21-00852","volume":"45","author":"M Uchida","year":"2022","unstructured":"Uchida M, Ushio S, Niimura T et al (2022) Renin-angiotensin-aldosterone system inhibitors prevent the onset of oxaliplatin-induced peripheral neuropathy: a retrospective multicenter study and in vitro evaluation. Biol Pharm Bull 45(2):226\u2013234. https:\/\/doi.org\/10.1248\/bpb.b21-00852","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"8193_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.clinthera.2018.05.011","volume":"40","author":"M Uchida","year":"2018","unstructured":"Uchida M, Kawazoe H, Takatori S et al (2018) Preventive effects of renin-angiotensin system inhibitors on oxaliplatin-induced peripheral neuropathy: a retrospective observational study. Clin Ther 40(7):1214-1222.e1. https:\/\/doi.org\/10.1016\/j.clinthera.2018.05.011","journal-title":"Clin Ther"},{"issue":"10","key":"8193_CR16","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.3390\/jcm11102939","volume":"11","author":"S Frachet","year":"2022","unstructured":"Frachet S, Danigo A, Labriffe M et al (2022) Renin-angiotensin-system inhibitors for the prevention of chemotherapy-induced peripheral neuropathy: OncoToxSRA, a preliminary cohort study. J Clin Med 11(10):2939. https:\/\/doi.org\/10.3390\/jcm11102939","journal-title":"J Clin Med"},{"key":"8193_CR17","unstructured":"Medical Data Vision Co., Ltd. Press release: updated database information 2019. [in Japanese]. www.mdv.co.jp\/press\/2019\/detail_1201.html, https:\/\/en.mdv.co.jp\/. Accessed 14 July 2023"},{"issue":"1","key":"8193_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10147-022-02264-z","volume":"28","author":"H Sakata","year":"2023","unstructured":"Sakata H, Murase M, Kato T et al (2023) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study. Int J Clin Oncol 28(1):139\u2013144. https:\/\/doi.org\/10.1007\/s10147-022-02264-z","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"8193_CR19","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.3802\/jgo.2022.33.e78","volume":"33","author":"A Ueda","year":"2022","unstructured":"Ueda A, Watari H, Mandai M et al (2022) Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database. J Gynecol Oncol 33(6):e78. https:\/\/doi.org\/10.3802\/jgo.2022.33.e78","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"8193_CR20","doi-asserted-by":"publisher","first-page":"e000053","DOI":"10.1136\/esmoopen-2016-000053","volume":"1","author":"Y Hirayama","year":"2016","unstructured":"Hirayama Y, Sasaki J, Dosaka-Akita H, Ishitani K (2016) Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology. ESMO Open 1(3):e000053. https:\/\/doi.org\/10.1136\/esmoopen-2016-000053","journal-title":"ESMO Open"},{"key":"8193_CR21","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083\u20133107. https:\/\/doi.org\/10.1002\/sim.3697","journal-title":"Stat Med"},{"key":"8193_CR22","unstructured":"R Core Team (2021) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.  https:\/\/www.R-project.org\/. Accessed 14 July 2023"},{"key":"8193_CR23","unstructured":"Ethical guidelines for medical and health research involving human subjects. https:\/\/www.lifescience.mext.go.jp\/files\/pdf\/n2181_01.pdf. Accessed December 16, 2022"},{"issue":"4","key":"8193_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s002280050471","volume":"54","author":"JF Hoogkamer","year":"1998","unstructured":"Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M et al (1998) Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function. Eur J Clin Pharmacol 54(4):341\u2013345. https:\/\/doi.org\/10.1007\/s002280050471","journal-title":"Eur J Clin Pharmacol"},{"issue":"12 Pt 1","key":"8193_CR25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1177\/009127000004001207","volume":"40","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Sch\u00f6ndorfer G, Roth W (2000) Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 40(12 Pt 1):1355\u20131364. https:\/\/doi.org\/10.1177\/009127000004001207","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"8193_CR26","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00004872-200106001-00005","volume":"19","author":"K von Bergmann","year":"2001","unstructured":"von Bergmann K, Laeis P, P\u00fcchler K, Sudhop T, Schwocho LR, Gonzalez L (2001) Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 19(1):S33-40. https:\/\/doi.org\/10.1097\/00004872-200106001-00005","journal-title":"J Hypertens Suppl"},{"issue":"1","key":"8193_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","volume":"33","author":"FH Hausheer","year":"2006","unstructured":"Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15\u201349. https:\/\/doi.org\/10.1053\/j.seminoncol.2005.12.010","journal-title":"Semin Oncol"},{"issue":"7","key":"8193_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1023\/a:1008344507482","volume":"9","author":"TJ Postma","year":"1998","unstructured":"Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9(7):739\u2013744. https:\/\/doi.org\/10.1023\/a:1008344507482","journal-title":"Ann Oncol"},{"key":"8193_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.10.018","volume":"70","author":"J Luo","year":"2017","unstructured":"Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22\u201333. https:\/\/doi.org\/10.1016\/j.ejca.2016.10.018","journal-title":"Eur J Cancer"},{"issue":"6","key":"8193_CR30","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00520-019-05063-x","volume":"28","author":"JS Gewandter","year":"2020","unstructured":"Gewandter JS, Kleckner AS, Marshall JH et al (2020) Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. Support Care Cancer 28(6):2553\u20132562. https:\/\/doi.org\/10.1007\/s00520-019-05063-x","journal-title":"Support Care Cancer"},{"issue":"2","key":"8193_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/pds.4374","volume":"27","author":"SR Newcomer","year":"2018","unstructured":"Newcomer SR, Kulldorff M, Xu S et al (2018) Bias from outcome misclassification in immunization schedule safety research. Pharmacoepidemiol Drug Saf 27(2):221\u2013228. https:\/\/doi.org\/10.1002\/pds.4374","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08193-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T09:15:25Z","timestamp":1703150125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08193-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["8193"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08193-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3169225\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects are not applied to clinical studies that use only anonymized data. The data used in this study were anonymized by the MDV. Therefore, informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Author Yasutaka Ihara, Miho Otani, Ryota Kawai, and Shingo Takatori declare they have no financial interests. Kenji Sawa received lecture fees in the past 36\u00a0months from Eli Lilly Japan, AstraZeneca, Ono Pharmaceutical, Nippon Kayaku, Chugai Pharmaceutical, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, and Kyowa Kirin. Takumi Imai received lecture fees in the past 36\u00a0months from JCR Pharmaceuticals and Kyowa Kirin. TK is an employee of Daiichi Sankyo, which owns the patent for and manufactures one of the study drugs (olmesartan). Tetsuya Kimura was involved only in the study design and discussion of the results and played no role in data processing or conducting the analyses. Ayumi Shintani received lecture fees in the past 36\u00a0months from AbbVie, AstraZeneca plc, Asahi Kasei Corporation, Astellas Pharma, Bayer Yakuhin, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Janssen Pharmaceutical, Kissei Pharmaceutical, Kyowa Kirin, Mallinckrodt Pharmaceuticals, Maruho, Merck Biopharma, Mitsubishi Tanabe Pharma Corporation, Nipro Corporation, Nippon Shinyaku, Novo Nordisk Pharma, Ono Pharmaceutical, Pfizer, Shionogi Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical Company Limited, and Torii Pharmaceutical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"730"}}